A biodegradable, biocompatible nanocarrier platform using nanohydroxyapatite rods to deliver gene-editing cargo directly into plant cells. Enables DNA delivery across plant cell walls for genome editing applications in crops including canola, soybean, and wheat, offering an alternative to conventional genetic transformation methods.
This research proposes a nanohydroxyapatite (nHA) rod-based delivery system for plant genetic engineering and gene editing. Conventional plant transformation methods often rely on Agrobacterium or biolistics, which can be costly, time-consuming, and limited by species compatibility. The proposed approach leverages nHA rods as nanocarriers that are small enough to traverse plant cell walls, biodegradable, and biocompatible, enabling direct delivery of molecular cargo such as plasmid DNA into plant tissues. The goal is to combine this nanobiotechnology with de novo meristem regeneration and genome editing to produce gene-edited plants more efficiently.
Key features:
The technology is currently at an early-to-mid stage of development. Transient gene expression has been demonstrated in multiple plant species, confirming that nHA-pDNA conjugates can deliver molecular cargo into plant tissues. The next phase focuses on optimizing the nanoparticles for larger gene-editing cargo loads, incorporating nuclear-targeting peptides, and producing stable gene-edited plantlets. The estimated timeline for this validation phase is approximately one year. Long-term translation targets major crops including canola, soybean, and wheat.
The University of South Dakota is a comprehensive public research university based in Vermillion with a statewide footprint through multiple campuses and professional programs. Industry collaboration is enabled by the USD Discovery District, a corporate–academic research park in Sioux Falls that offers flexible R&D space and adjacency to growing employers. The Sanford School of Medicine operates across regional sites and clinical departments embedded with major hospital systems, providing access to clinicians, patients and data for translational work. Research is supported by competitive federal funding and centralized sponsored-programs administration. A dedicated technology transfer office guides IP, licensing and startup formation to speed commercialization.